{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:32:31Z","timestamp":1785767551089,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jid.2018.05.027","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T19:54:23Z","timestamp":1532634863000},"page":"1911-1916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["JAK Inhibitors for Treatment of Alopecia\u00a0Areata"],"prefix":"10.1016","volume":"138","author":[{"given":"Eddy H.C.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte N.","family":"Sallee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina I.","family":"Tejeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Christiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2018.05.027_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000445182","article-title":"Transient efficacy of tofacitinib in alopecia areata universalis","volume":"8","author":"Anzengruber","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib3","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1038\/ncomms6966","article-title":"Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci","volume":"6","author":"Betz","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jid.2018.05.027_bib4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jaad.2010.08.032","article-title":"Comorbidity profiles among patients with alopecia areata: the importance of\u00a0onset age, a nationwide population-based\u00a0study","volume":"65","author":"Chu","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib5","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one\u00a0stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","article-title":"Tofacitinib citrate for the\u00a0treatment of nail dystrophy\u00a0associated with\u00a0alopecia universalis","volume":"152","author":"Dhayalan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/nm.3685","article-title":"Inhibiting Janus kinases to treat alopecia areata","volume":"20","author":"Divito","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2018.05.027_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/all.13128","article-title":"Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2","volume":"72","author":"Drucker","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jid.2018.05.027_bib11","first-page":"47","article-title":"Excellent response to tofacitinib treatment in a patient with alopecia universalis","volume":"26","author":"Erduran","year":"2017","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.jid.2018.05.027_bib12","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000450848","article-title":"Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report","volume":"8","author":"Ferreira","year":"2016","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2133.2006.07377.x","article-title":"Interferon-gamma-deficient mice are resistant to the development of alopecia areata","volume":"155","author":"Freyschmidt-Paul","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.2010.09775.x","article-title":"Type 1 interferon signature in the scalp lesions of alopecia areata","volume":"163","author":"Ghoreishi","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.autrev.2016.03.008","article-title":"Alopecia areata: animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies","volume":"15","author":"Gilhar","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jid.2018.05.027_bib16","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/jdv.13598","article-title":"Efficacy of tofacitinib in treatment of alopecia universalis in two patients","volume":"30","author":"Gupta","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2018.05.027_bib17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib18","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.jaci.2014.12.1867","article-title":"Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation","volume":"135","author":"Higgins","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.05.027_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jid.2018.05.027_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to\u00a0severe patch-type alopecia areata, totalis, and universalis","author":"Jabbari","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"15","key":"10.1016\/j.jid.2018.05.027_bib22","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2018.05.027_bib23","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5021\/ad.2014.26.6.722","article-title":"Differences in comorbidity profiles between early-onset and late-onset\u00a0alopecia areata patients: a retrospective study of 871 Korean patients","volume":"26","author":"Lee","year":"2014","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib24","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"15","key":"10.1016\/j.jid.2018.05.027_bib25","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2018.05.027_bib26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00403-016-1652-9","article-title":"ULBP3: a marker for alopecia areata incognita","volume":"308","author":"Moftah","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2018.05.027_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2340\/00015555-2491","article-title":"Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman","volume":"97","author":"Mrowietz","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"Suppl. 2","key":"10.1016\/j.jid.2018.05.027_bib28","doi-asserted-by":"crossref","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","article-title":"Janus kinase inhibitors in autoimmune diseases","volume":"72","author":"O'Shea","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2018.05.027_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2018.05.027_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.jid.2018.05.027_bib31","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jisp.2017.10.014","article-title":"Hair follicle immune privilege revisited: the key to alopecia areata management","volume":"19","author":"Paus","year":"2018","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"7302","key":"10.1016\/j.jid.2018.05.027_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","volume":"466","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jid.2018.05.027_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jid.2018.05.027_bib34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.7326\/L16-0125","article-title":"Reversal of alopecia universalis by tofacitinib: a case report","volume":"165","author":"Scheinberg","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jid.2018.05.027_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jid.2018.05.027_bib36","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaad.2017.04.1142","article-title":"Alopecia areata: an appraisal of new treatment approaches and overview of current therapies","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib38","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/ijd.13598","article-title":"Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring","volume":"56","author":"Vandiver","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2018.05.027_bib39","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jid.2018.05.027_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaci.2017.10.028","article-title":"Novel therapies for alopecia areata: the era of rational drug development","volume":"141","author":"Wang","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2018.05.027_bib41","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18320554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X18320554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:10:39Z","timestamp":1758301839000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X18320554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0022202X18320554"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2018.05.027","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK Inhibitors for Treatment of Alopecia\u00a0Areata","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2018.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}